Stockreport

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

SAB Biotherapeutics, Inc.  (SABS) 
PDF MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platfo [Read more]